12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AMG 145: Phase III started

Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Product: AMG 145
Business: Endocrine/Metabolic
Molecular target: Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Description: Human mAb against proprotein convertase subtilisin/kexin type 9...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >